Lionheart Health Honored as 2025 Top Implantable Stimulator Developer by MedTech Outlook Magazine

Lionheart Health, Inc., a forefront biotech and medical device company, has been awarded the title of Top Implantable Stimulator Developer of the Year by MedTech Outlook Magazine in 2025. This accolade highlights the company's pioneering work with its KlothoImplant™ and MicroImplant™ technologies, which are designed to deliver precise bioelectric signals to control regenerative protein expression. These proteins are crucial for directing stem cells to target organs, fostering muscle growth, enhancing blood vessel development, mitigating inflammation, and preventing calcification.

Brian Lasater, Chief Technology Officer at Leonhardt Ventures LLC and Lionheart Health, Inc., emphasized the transformative potential of these micro implant stimulators. According to Lasater, the technology can command stem cell activities and release proteins that combat aging, promote muscle development, and address chronic inflammation, among other benefits.

In partnership with Leonhardt Ventures LLC, Lionheart Health has not only patented but also rigorously tested its bioelectric stimulation platform across a spectrum of applications. These include the regeneration of vital organs like the heart, kidneys, and brain, as well as advancements in blood pressure management and hearing restoration. The company's collaboration with OEM manufacturing partners has yielded a diverse array of devices, from benchtop stimulators to miniaturized implants, now recognized for their success in passing stringent testing phases, including those for complete heart and kidney regeneration.

MedTech Outlook's recognition of Lionheart Health underscores the significant strides made in medical technology, particularly in devices that offer tangible benefits to healthcare providers and patients alike. The publication plays a pivotal role in bridging the gap between emerging medical technologies and the healthcare sector.

Lasater expressed gratitude for the recognition, noting the company's robust intellectual property portfolio, which includes over 500 patents and pending claims, along with multiple FDA 510(k) clearances. The company's stimulators are capable of inducing the release of specific regenerative proteins, such as SDF-1 and PDGF for stem cell homing, VEGF and eNOS for circulation improvement, and various anti-inflammatory and muscle-building proteins.

Further cementing its position in the medical technology field, Lionheart Health was recently named a Top 40 semifinalist in the XPRIZE Healthspan competition, in pursuit of an $81 million grand prize. This achievement, coupled with the MedTech Outlook award, highlights the company's commitment to advancing healthspan and longevity through innovative bioelectric signaling technologies.

For more information on Lionheart Health's groundbreaking work, visit https://www.LionheartLongevity.com, https://www.lionhearthealthstim.com, and https://www.LeonhardtVentures.com.